Skin inflammatory and pruritic signaling pathways

Skin inflammatory and pruritic signaling pathways encompass the integrated biological processes involving immune cells, keratinocytes, and sensory neurons that mediate skin inflammation and the sensation of itch. Central to these pathways is the neuro-immune axis, where cytokines such as Interleukin-31 (IL-31), Interleukin-4 (IL-4), and Interleukin-13 (IL-13) act on specific receptors to trigger downstream signaling, most notably the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway (PubMed: 30107239). These interactions lead to the recruitment of inflammatory cells and the sensitization of peripheral pruriceptors, resulting in the characteristic itch-scratch cycle seen in conditions like atopic dermatitis and prurigo nodularis (PubMed: 29330110). Modern therapeutics target these pathways by inhibiting specific cytokines (e.g., Dupilumab for IL-4/13, Nemolizumab for IL-31) or by blocking intracellular signaling enzymes like JAK1 to provide rapid relief from both inflammation and pruritus (PubMed: 31108154). This complex signaling network represents a major focus for dermatological drug development aimed at treating chronic inflammatory skin diseases.

Other names

Itch-scratch cycleNeuro-immune pruritic axisTh2-mediated skin inflammationPruritogenic signaling pathways

Inhibition of Th2-mediated cytokine signaling (IL-4, IL-13, IL-31) and the JAK-STAT pathway to suppress neuro-immune crosstalk and interrupt the itch-scratch cycle.